Abstract
Defining the sequence of the human genome has brought with it a wealth of potential drug targets of uncertain biology. For pharmaceutical firms to reduce the risk of drug failure after long, expensive clinical development programs, accurate information is required about the biological effects of the compounds being tested. Therefore, there is a strong need for biomarkers that can assist in unraveling the complex biology of these novel drug targets and their use during the drug development process is no longer optional.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Sindern E. Role of Chemokines and Their Receptors in the Pathogenesis of Multiple Sclerosis. Front Biosci 2004 Jan 1; 9:457–463
Papadakis KA. Chemokines in Inflammatory Bowel Disease. Curr Allergy Asthma Rep. 2004 Jan; 4(1):83–89
Weinshilboum R. Inheritance and Drug Response. N Engl J Med 2003, Feb 6; 348(6):529–537
Sheikine Y, and Hansson GK. Chemokines and Atherosclerosis. Ann Med 2004; 36(2):98–118
Loetscher P, and Moser B. Homing Chemokines in Rheumatoid Arthritis. Arthritis Res 2002; 4(4):233–236
Gerard C, and Rollins BJ. Chemokines and Disease. Nat Immunol. 2001 Feb; 2(2):108–115
Gladue RP, Zwillich SH, Clucas AT, and Brown MF. CCR1 Antagonists for the Treatment of Autoimmune Diseases. Curr Opin Investig Drugs 2004 May; 5(5):499–504
Lee SC, Brummet ME, Shahabuddin S, Woodworth TG, Georas SN, Leiferman KM, Gilman SC, Stellato C, Gladue RP, and Schleimer RP, et. al. Cutaneous Injection of Human Subjects with Macrophage Inflammatory Protein-1· Induces Significant Recruitment of Neutrophils and Monocytes. Journal of Immunology, 2000, 164:3392–3401
Sabroe I, Lloyd CM, Whyte MK, Dower SK, Williams TJ, and Pease JE. Chemokines, Innate and Adaptive Immunity, and Respiratory Disease. Eur Respir J. 2002 Feb; 19(2):350–355
Personal Communication
Trepiccho William, Millennium Pharmaceuticals, Inc., Personal Communication, 2004.
Symposia
Lekstrom-Himes J, Shadick N, Meyer J, Lillie J, Chun M, Gutierrez-Ramos JC, Weinblatt M, Weiner H, Khoury S, and Ginsburg GS. Therapeutic Response Biomarkers for Use in Proof of Concept Clinical Trials: Discovery and Validation of Biomarkers Sets Using Large Patient Registries. Keystone Symposia, Biomarkers in Drug Development, Santa Fe, NM, January 2004.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2006 American Association of Pharmaceutical Scientists
About this chapter
Cite this chapter
Ginsburg, G.S., Lekstrom-Himes, J., Trepicchio, W. (2006). Optimizing Biomarker Development for Clinical Studies at the Lead Optimization Stage of Drug Development. In: Borchardt, R.T., Kerns, E.H., Hageman, M.J., Thakker, D.R., Stevens, J.L. (eds) Optimizing the “Drug-Like” Properties of Leads in Drug Discovery. Biotechnology: Pharmaceutical Aspects, vol IV. Springer, New York, NY. https://doi.org/10.1007/978-0-387-44961-6_17
Download citation
DOI: https://doi.org/10.1007/978-0-387-44961-6_17
Publisher Name: Springer, New York, NY
Print ISBN: 978-0-387-34056-2
Online ISBN: 978-0-387-44961-6
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)
